234P Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3)
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI